Chorea associated with antiphospholipid antibodies

Czech version

Authors: Balajková Veronika
Authors‘ workplace: Revmatologický ústav Praha
Published in: Čes. Revmatol., 31, 2023, No. 2, p. 82-88.
Category: Reviews

Overview

Balajková V. Chorea associated with antiphospholipid antibodies

Chorea is one of the dyskinetic syndromes consisting of involuntary movements affecting the limbs, trunk, neck, or face, which can shift from one part of the body to another. It is a movement disorder that can be related to autoimmune diseases, especially to the presence of antiphospholipid antibodies (APLA). Choreatic movements are associated with the isolated presence of plasma APLA, with primary or secondary antiphospholipid syndrome, or with systemic lupus erythematosus. The highest incidence of APLA-related chorea is found in children and women. Symptoms of chorea are usually subacute and the course is monophasic. Choreatic movements can be focal or generalized. High plasma titers of APLA in a patient with chorea may suggest a diagnosis of APLA-related chorea. Functional neuroimaging techniques can be helpful in diagnosis. The etiology of the movement disorder is not known in detail, but the procoagulant, as well as the neurotoxic effect of APLA, is assumed, which leads to a malfunction of basal ganglia cells and the development of neuroinflammation with a disorder of the blood-brain barrier. Patients with APLA-related chorea are at increased risk of thrombosis and other complications and should therefore be adequately treated.

Keywords:

Systemic lupus erythematosus – antiphospholipid antibodies – chorea

Sources

Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Practical neurology 2007; 7(6): 360–373.
Sanger TD, Chen D, Fehlings DL, Hallett M, Lang AE, Mink JW, et al. Definition and classification of hyperkinetic movements in childhood. Movement disorders: official journal of the Movement Disorder Society 2010; 25(11): 1538–1549.
Roth JK, J. Choreatické dyskineze. Neurologie por praxi 2011; 12(1): 16–17.
Peluso S, Antenora A, De Rosa A, Roca A, Maddaluno G, Brescia Morra V, et al. Antiphospholipid–related chorea. Frontiers in neurology 2012; 3: 150.
Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis and rheumatism 2002; 46(4): 1019–1027.
Asif S, Bali A, Dang AK, Gonzalez DA, Kumar R. Neurological and Neuropsychiatric Manifestations of Antiphospholipid-Antibody Syndrome (APS). Cureus 2022; 14(6): e26022.
Baizabal-Carvallo JF, Bonnet C, Jankovic J. Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. Journal of neural transmission 2013; 120(11): 1579–1589.
Plowman EK, Okun MS. Antiphospholipid syndrome and other lupus–related movement disorders. Handbook of clinical neurology 2011; 100: 237–245.
Sorice M, Longo A, Capozzi A, Garofalo T, Misasi R, Alessandri C, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis and rheumatism 2007; 56(8): 2687–2697.
Boles J, Mackman N. Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus 2010; 19(4): 370–378.
Capozzi A, Manganelli V, Riitano G, Recalchi S, Truglia S, Alessandri C, et al. Tissue factor over–expression in platelets of patients with anti–phospholipid syndrome: induction role of anti-beta2-GPI antibodies. Clinical and experimental immunology 2019; 196(1): 59–66.
Man YL, Sanna G. Neuropsychiatric Manifestations of Antiphospholipid Syndrome-A Narrative Review. Brain sciences 2022; 12(1).
Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thrombosis and haemostasis 1998; 79(2): 276–281.
Lopez-Pedrera C, Aguirre MA, Buendia P, Barbarroja N, RuizLimon P, Collantes-Estevez E, et al. Differential expression of protease–activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis and rheumatism 2010; 62(3): 869–877.
Proulle V, Furie RA, Merrill-Skoloff G, Furie BC, Furie B. Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS. Blood 2014; 124(4): 611–622.
Yalavarthi S, Gould TJ, Rao AN, Mazza LF, Morris AE, NunezAlvarez C, et al. Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome. Arthritis & rheumatology (Hoboken, NJ) 2015; 67(11): 2990–3003.

Breen KA, Seed P, Parmar K, Moore GW, Stuart–Smith SE, Hunt BJ. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thrombosis and haemostasis 2012; 107(3): 423–429.
de Laat B, Eckmann CM, van Schagen M, Meijer AB, Mertens K, van Mourik JA. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis 2008; 19(8): 757–764.
Ieko M, Yoshida M, Naito S, Nakabayashi T, Kanazawa K, Mizukami K, et al. Increase in plasma thrombin – activatable fibrinolysis inhibitor may not contribute to thrombotic tendency in antiphospholipid syndrome because of inhibitory potential of antiphospholipid antibodies toward TAFI activation. International journal of hematology 2010; 91(5): 776–783.
Liestol S, Sandset PM, Jacobsen EM, Mowinckel MC, Wisloff F. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. British journal of haematology 2007; 136(1): 131–137.
Rahgozar S, Yang Q, Giannakopoulos B, Yan X, Miyakis S, Krilis SA. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation. Arthritis and rheumatism 2007; 56(2): 605–613.
de Laat B, Wu XX, van Lummel M, Derksen RH, de Groot PG, Rand JH. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5. Blood 2007; 109(4): 1490–1494.
Lejrefors LA, et. al. Antiphospholipid-Related Chorea: Two CAse Reports and Role of Metabolic Imaging. Movement Disorders Clinical Practice 2022; 9(4): 516–521.
Soltesz P, Der H, Veres K, Laczik R, Sipka S, Szegedi G, et al. Immunological features of primary anti–phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford, England) 2008; 47(11): 1628–1634.
Katzav A, Shoenfeld Y, Chapman J. The pathogenesis of neural injury in animal models of the antiphospholipid syndrome. Clinical reviews in allergy & immunology 2010; 38(2–3): 196–200.
Gris JC, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thrombosis research 2015; 135(Suppl 1): S56–59.
Gris JC, Brenner B. Antiphospholipid antibodies: neuropsychiatric presentations. Seminars in thrombosis and hemostasis 2013; 39(8): 935–942.
Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus 2003; 12(6): 436–442.
Dale RC, Yin K, Ding A, Merheb V, Varadkhar S, McKay D, et al. Antibody binding to neuronal surface in movement disorders associated with lupus and antiphospholipid antibodies. Developmental medicine and child neurology 2011; 53(6): 522– 528.
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis and rheumatism 1999; 42(4): 599–608.
Joseph FG, Lammie GA, Scolding NJ. CNS lupus: a study of 41 patients. Neurology 2007; 69(7): 644–654.
Spinosa MJ, Bandeira M, Liberalesso PB, Vieira SC, Janz LL, Jr., Sa EG, et al. Clinical, laboratory and neuroimage findings in juvenile systemic lupus erythematosus presenting involvement of the nervous system. Arquivos de neuro-psiquiatria 2007; 65(2B): 433–439.

Poil AR, Yousef Khan F, Lutf A, Hammoudeh M. Chorea as the First and Only Manifestation of Systemic Lupus Erythematosus. Case Reports in Rheumatology 2012; 2012: 907402.
Baizabal-Carvallo JF, Alonso-Juarez M, Koslowski M. Chorea in systemic lupus erythematosus. Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases 2011; 17(2): 69–72.
Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, RamseyGoldman R, et al. 2019 European League Against Rheumatism/ American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the rheumatic diseases 2019; 78(9): 1151–1159.
Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. Journal of autoimmunity 2017; 76: 10–20.
Safarpour D, Buckingham S, Jabbari B. Chorea associated with high titers of antiphospholipid antibodies in the absence of antiphospholipid antibody syndrome. Tremor and other hyperkinetic movements 2015; 5: 294.
Asherson RA. New subsets of the antiphospholipid syndrome in 2006: “PRE–APS” (probable APS) and microangiopathic antiphospholipid syndromes (MAPS). Autoimmunity reviews 2006; 6(2): 76–80.
Orzechowski NM, Wolanskyj AP, Ahlskog JE, Kumar N, Moder KG. Antiphospholipid antibody-associated chorea. The Journal of rheumatology 2008; 35(11): 2165–2170.
Tarr T, Lakos G, Bhattoa HP, Soltesz P, Shoenfeld Y, Szegedi G, et al. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clinical reviews in allergy & immunology 2007; 32(2): 131–137.
Ajmani S, Misra DP, Lawrence A. SLE presenting as migratory arthritis, chorea and nephritis. Mediterranean journal of rheumatology 2018; 29(1): 43–45.
Avcin T, Benseler SM, Tyrrell PN, Cucnik S, Silverman ED. A follow-up study of antiphospholipid antibodies and associated neuropsychiatric manifestations in 137 children with systemic lupus erythematosus. Arthritis and rheumatism 2008; 59(2): 206–213.
Miranda M, Cardoso F, Giovannoni G, Church A. Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies. Journal of neurology, neurosurgery, and psychiatry 2004; 75(2): 327–328.
Sciascia S, Radin M, Cecchi I, Levy RA, Erkan D. 16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. Lupus 2021; 30(8): 1314–1326.
Mustafa R. Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome. Current Neurology and Neuroscience Reports 2022; 22(10): 589–600.
Reiner P, Galanaud D, Leroux G, Vidailhet M, Haroche J, Huong du LT, et al. Long-term outcome of 32 patients with chorea and systemic lupus erythematosus or antiphospholipid antibodies. Movement disorders: official journal of the Movement Disorder Society 2011; 26(13): 2422–2427.
Galanaud D, Dormont D, Marsault C, Wechsler B, Piette JC. Brain MRI in patients with past lupus-associated chorea. Stroke 2000; 31(12): 3079–3083.
Demonty J, Gonce M, Ribai P, Verellen–Dumoulin C, Hustinx R. Chorea associated with anti-phospholipid antibodies: case report. Acta clinica Belgica 2010; 65(5): 350–353.
Harel L, Zecharia A, Straussberg R, Volovitz B, Amir J. Successful treatment of rheumatic chorea with carbamazepine. Pediatric neurology 2000; 23(2): 147–151.
Ruffatti A, Del Ross T, Ciprian M, Bertero MT, Sciascia S, Scarpato S, et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Annals of the rheumatic diseases 2011; 70(6): 1083–1086.
Tektonidou MG. Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis. Journal of autoimmunity 2022; 128: 102813.
Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus 2018; 27(3): 399–406.
Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmunity reviews 2015; 14(4): 358–362.
Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the rheumatic diseases 2019; 78(10): 1296–1304.
Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nature reviews Rheumatology 2010; 6(6): 358–367.
Ueda Y, Takahashi Y, Yamashita H, Kano T, Mimori A. Chorea in systematic lupus erythematosus; a case report. Nihon Rinsho Men’eki Gakkai kaishi = Japanese journal of clinical immunology 2013; 36(6): 467–472.
Lazurova I, Macejova Z, Benhatchi K, Oetterova M, Antolova E, Asherson RA, et al. Efficacy of intravenous immunoglobulin treatment in lupus erythematosus chorea. Clinical rheumatology 2007; 26(12): 2145–2147.
D’Hont A, De Wachter M, Driesen Y, Sabato V, Joos R, Ceulemans B. Successful Rituximab Therapy for Pediatric Antiphospholipid– Related Chorea: A Case Report and Review of the Literature. Neuropediatrics 2022; 53(5): 366–369.
Somaily MA, HI, Ali Buhran L. Alhasansh A. Systemic lupus Erythematosusu associated chorea treated successfully wuth Rituximab Case report. Annals of Arthritis and Clinical rheumatology 2020; 3(1).

Labels

Dermatology & STDs Paediatric rheumatology Rheumatology

EDITORIAL

Prof. MUDr. Milan Adam, DrSc., dr.h.c.

Laudatio for the ninetieth birthday of Zbyněk Hrnčíř, MD, DSc, professor of medicine

Recommendations of the Czech Society of Rheumatology for the treatment of psoriatic arthritis

Mixed, overlap, and undifferentiated connective tissue diseases in current rheumatology

Rheumatic diseases and treatment with checkpoint inhibitors

Complicated course of systemic lupus erythematosus

Abstracts of the XIX. seminar of young rheumatologists

Dana Němcová, MD celebrated a significant life anniversary

Life anniversary of Šárka Forejtová, MD

Article was published in

Czech Rheumatology

2023 Issue 2